Literature DB >> 17905482

Screening of innate immune receptors in neurodegenerative diseases: a similar pattern.

Maryse Letiembre1, Yang Liu, Silke Walter, Wenlin Hao, Tatjana Pfander, Arne Wrede, Walter Schulz-Schaeffer, Klaus Fassbender.   

Abstract

In Alzheimer's disease (AD), Parkinson's disease (PD), dementia with Lewy bodies (DLB) and amyotrophic lateral sclerosis (ALS), neuroinflammatory responses are considered to contribute to neuronal injury. Recently, the innate immune receptors, toll-like receptors (TLRs) and the LPS receptor (CD14) have been related to neurodegeneration. In this study, we systematically assessed the expression of most TLRs and CD14 in AD, PD/DLB and ALS using murine models of these diseases and human post-mortem brain tissues. A common upregulation of TLR2 and CD14 was found in all three animal models. While these two receptors could also be detected in AD patient tissues, they were absent from DLB and ALS tissues. This uniform pattern of innate immune response in animal models of neurodegenerative diseases clearly indicates that this response is part of a non-specific neuroinflammatory effector phase rather than a disease-specific event. The less dynamic disease progression in humans and the location (extracellular versus intracellular) of the aggregated proteins deposits might explain the divergent results seen between animal models and human tissues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17905482     DOI: 10.1016/j.neurobiolaging.2007.08.018

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  100 in total

1.  Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy.

Authors:  Changyoun Kim; Edward Rockenstein; Brian Spencer; Hyung-Koo Kim; Anthony Adame; Margarita Trejo; Klodjan Stafa; He-Jin Lee; Seung-Jae Lee; Eliezer Masliah
Journal:  Cell Rep       Date:  2015-10-17       Impact factor: 9.423

Review 2.  Immune-mediated processes in neurodegeneration: where do we stand?

Authors:  Marc Fakhoury
Journal:  J Neurol       Date:  2016-02-12       Impact factor: 4.849

Review 3.  Inflammation in the early stages of neurodegenerative pathology.

Authors:  Preeti J Khandelwal; Alexander M Herman; Charbel E-H Moussa
Journal:  J Neuroimmunol       Date:  2011-08-05       Impact factor: 3.478

Review 4.  Interplay Between Exosomes, microRNAs and Toll-Like Receptors in Brain Disorders.

Authors:  Vera Paschon; Silvia Honda Takada; Juliane Midori Ikebara; Erica Sousa; Reza Raeisossadati; Henning Ulrich; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2015-04-11       Impact factor: 5.590

5.  CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation.

Authors:  Erin G Reed-Geaghan; Julie C Savage; Amy G Hise; Gary E Landreth
Journal:  J Neurosci       Date:  2009-09-23       Impact factor: 6.167

Review 6.  Inflammation, microglia, and Alzheimer's disease.

Authors:  Brent Cameron; Gary E Landreth
Journal:  Neurobiol Dis       Date:  2009-10-13       Impact factor: 5.996

7.  The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis.

Authors:  Xibin Liang; Qian Wang; Ju Shi; Ludmila Lokteva; Richard M Breyer; Thomas J Montine; Katrin Andreasson
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

Review 8.  Toll-like receptors in neurodegeneration.

Authors:  Eitan Okun; Kathleen J Griffioen; Justin D Lathia; Sung-Chun Tang; Mark P Mattson; Thiruma V Arumugam
Journal:  Brain Res Rev       Date:  2008-09-12

9.  Screening of Toll-like receptors expression in multiple system atrophy brains.

Authors:  Tomasz Brudek; Kristian Winge; Tina Klitmøller Agander; Bente Pakkenberg
Journal:  Neurochem Res       Date:  2013-03-23       Impact factor: 3.996

Review 10.  Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application.

Authors:  Dorit Trudler; Dorit Farfara; Dan Frenkel
Journal:  Mediators Inflamm       Date:  2010-07-25       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.